NEW YORK, April 11, 2012 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of ViroPharma, Inc. ("ViroPharma" or the "Company") (NasdaqGS: VPHM), concerning whether the company and certain of its officers and directors have violated federal securities laws.
On Tuesday April 10, 2012, shares of ViroPharma fell over 17%, after the Company revealed that it was under investigation by the Federal Trade Commission ("FTC"). The FTC is investigating the company for possible unfair practices with regards to the marketing of Vancocin. ViroPharma launched a Citizens Petition in 2006 to deny Watson Pharmaceuticals the right to launch a generic version of Vancocin, claiming it was too similar to the patented version. On April, 9, 2012, the FDA shot down that petition, clearing the path for Watson to bring its generic to market.
If you are aware of any facts relating to this investigation, or purchased shares of ViroPharma, you can assist this investigation by contacting either Peretz Bronstein or Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email [email protected]. Those who inquire by e-mail are encouraged to include their mailing address and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman, 212-697-6484
SOURCE Bronstein, Gewirtz & Grossman, LLC